Analytical and clinical evaluation of a new urinary tumor marker: Bladder tumor fibronectin in diagnosis and follow-up of bladder cancer

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 8, 2003, Pages 1069-1074

  Mutlu, Nilgun ^a   Turkeri, Levent ^a   Emerk, Kaya ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bladder cancer; Cancer diagnosis; Fibronectin; Tumor marker

Indexed keywords

CREATININE; FIBRONECTIN; TUMOR MARKER;

ANALYTIC METHOD; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CHEMOLUMINESCENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE URINE LEVEL; CYSTOSCOPY; DATA ANALYSIS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IN VITRO STUDY; LABORATORY AUTOMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SENSITIVITY AND SPECIFICITY; SOLID; SUPERFICIAL CANCER;

CHEMILUMINESCENT MEASUREMENTS; CREATINE; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; FIBRONECTINS; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; MALE; RECURRENCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0041352332     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.165     Document Type: Article

References (23)

1. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13:291-8.
2. Shirai T, Fukushima S, Hirose M, Ohshima M, Ito N. Epithelial lesions of the urinary bladder in three hundred and thirteen autopsy cases. Jpn J Cancer Res 1987; 78:1073-80.
3. Herr HW, Lamm DL. Management of superficial bladder cancer. Principles and practice of genitourinary oncology. Raghovan D, Scher HI, Liebel SA, Lange PH, editors. Philadelphia: Lippincott-Rowen Publishers, 1997:273-80.
4. Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O. Urine cytology, tumor markers and bladder cancer. Br J Urol 1998; 82:647-54.
5. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clin Chem 2000; 46:595-605.
6. Hynes RO, Yamada KM. Fibronectins: multifunctional modular glycoproteins. J Cell Biol 1982; 95:369-77.
7. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopatological aspects. Virch Arch 1996; 429: 311-22.
8. Schwarzbauer JE, Sechler JL. Fibronectin fibrillogenesis: a paradigm for extracellular matrix assembly. Curr Opin Cell Biol 1999; 11:622-7.
9. Sottile J, Wiley S. Assembly of aminoterminal fibronectin dimers into the extra cellular matrix. J Biol Chem 1994; 269:17192-8.
10. Katayama M, Hino F, Kamihagi K, Sekiguchi K, Titani K, Kato I. Urinary fibronectin fragments (a potential tumor marker) measured by immunoenzymometric assay with domain-specific monoclonal antibodies. Clin Chem 1991; 37/3:466-71.
11. Katayama M, Kamihagi K, Nakagawa K, Akiyama T, Sano Y, Ouchi R, et al. Increased fragmentation of urinary fibronectin in cancer patients detected by immunoenzymometric assay using domain-specific monoclonal antibodies. Clin Chim Acta 1993; 217:115-28.
12. Malmström PU, Larsson A, Johansson S. Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer. Br J Urol 1993; 72:307-10.
13. Webb KS, Lin GH. Urinary fibronectin potential as a biomarker in prostatic cancer. Inv Urol 1980; 17:401-4.
14. Nagai T, Yamakawa N, Aota S, Yamada SS, Akiyama SK, Olden K, et al, Monoclonal antibody characterization of two distant sites required for function of the central cell-binding domain of fibronectin in cell adhesion, cell migration, and matrix assembly. J Cell Biol 1991; 114:1295-305.
15. Zweig MH, Canpbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39/4:561-77.
16. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990; 322:1129-38.
17. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol 2001; 165:1067-77.
18. Rouslahti E. Fibronectin and its integrin receptors in cancer. Adv Cancer Res 1999; 76:1-20.
19. Wiener HG, Vooijs GP, Van't Hof- Grootenboer B. Accuracy of urinary cytology in the diagnosis of primary and recurrent bladder cancer. Acta Cytol 1993; 37:163-9.
20. Carbayo MS, Urrutia M, Gonzales de Buitrago JM, Navajo JA. Evaluation of two urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin Cancer Res 2000; 6:3585-94.
21. Ross JS, Cohen MB. Biomarkers for the detection of bladder cancer. Adv Anat Pathol 2001; 8:37-45.
22. Sarosdy MF, Schellammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of multi-target fluorescence in situ hybridization assay for detection of bladder cancer. J Urol 2002; 168:1950-4.
23. Ishiwata S, Tokahashi S, Homma Y, Tanaka Y, Kameyama S, Hosaka Y, et al, Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. Urology 2001; 57:811-5.